Sagimet's Denifanstat Shows Sustained Efficacy in Acne Trials, U.S. Phase 3 Underway

  • Sagimet to present 52-week Phase 3 data for denifanstat in acne at Fall Clinical Dermatology Conference, showing 57% IGA success and 72% lesion reduction.
  • U.S. Phase 3 AURORA trial for denifanstat now screening patients with IRB approvals in place.
  • Ascletis' NDA submission for denifanstat in China accepted by NMPA in December 2025.
  • Denifanstat demonstrated sustained efficacy through 52 weeks in open-label extension trial.

Sagimet's positive Phase 3 data for denifanstat reinforces the potential of FASN inhibition as a novel oral treatment for moderate to severe acne. The U.S. Phase 3 trial initiation marks a critical step in Sagimet's strategy to expand denifanstat's global reach, following Ascletis' regulatory progress in China. The dermatology market, particularly for acne treatments, remains underserved for long-term solutions, making denifanstat's sustained efficacy a key differentiator.

Regulatory Pathway
Whether Ascletis can secure NMPA approval for denifanstat in China and its potential impact on Sagimet's global strategy.
Clinical Execution
The pace at which Sagimet can enroll and complete the U.S. Phase 3 AURORA trial, particularly among adolescent patients.
Market Differentiation
How denifanstat's long-term efficacy data will position it against existing acne treatments in a competitive dermatology market.